CARGO Therapeutics is developing tri-specific CAR T-cell therapies designed to target and eliminate B-cell lymphoma cells effectively. This approach aims to provide patients with potentially curative treatment options that traditional therapies may not achieve.
Funding
$110M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
B-cell lymphomas often relapse or become resistant to standard treatments, including traditional CAR T-cell therapies, leaving patients with limited options and poor prognoses. The complexity of targeting lymphoma cells while sparing healthy B-cells poses a significant challenge in developing effective and safe therapies.
Solution
CARGO Therapeutics is developing a pipeline of tri-specific CAR T-cell therapies engineered to more effectively target and eliminate B-cell lymphoma cells. Their CAR T-cell constructs are designed with innovative targeting domains to enhance specificity and reduce off-target effects, potentially leading to improved efficacy and safety profiles. By targeting multiple antigens on lymphoma cells, these therapies aim to overcome tumor heterogeneity and prevent immune escape, offering patients a potentially curative treatment option. CARGO's approach seeks to outsmart cancer by delivering more cures for patients with advanced B-cell lymphomas.
Target Audience
The primary target audience includes patients with relapsed or refractory B-cell lymphomas who have failed previous lines of therapy, as well as hematologists and oncologists specializing in lymphoma treatment.
Features
- Tri-specific CAR T-cell constructs designed to target multiple antigens on B-cell lymphoma cells
- Enhanced specificity to minimize off-target effects and reduce toxicity
- Innovative targeting domains to improve CAR T-cell engagement and activation
- Allogeneic platform for potential "off-the-shelf" CAR T-cell therapies